Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Ltd (NQ: ARCT )

21.97 -0.94 (-4.10%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 367,286
Open 22.35
Bid (Size) 21.02 (2)
Ask (Size) 24.09 (1)
Prev. Close 22.91
Today's Range 21.94 - 23.17
52wk Range 11.70 - 31.41
Shares Outstanding 26,492,869
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire

Performance

YTD
+31.56%
+31.56%
1 Month
+31.95%
+31.95%
3 Month
-4.31%
-4.31%
6 Month
+4.52%
+4.52%
1 Year
-9.48%
-9.48%

More News

Read More
Arcturus Therapeutics's Return On Capital Employed Overview
Via Benzinga
Arcturus Appoints John Markels, Ph.D. to its Board of Directors
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Why Arcturus Therapeutics Stock Is Skyrocketing Today
Via The Motley Fool
Where Arcturus Therapeutics Stands With Analysts
Via Benzinga
Why CSL Ltd Stock Could Be Worth a Look
Via MarketBeat
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022
Via Benzinga
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines
Via Benzinga
Arcturus Therapeutics to Present at the Following Investor Conferences in November
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
Via Benzinga
United Therapeutics, Super Micro Computer, Novo Nordisk And Other Big Gainers From Wednesday
Via Benzinga
Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why Is Rogers Corporation (ROG) Stock Down 44% Today?
Via InvestorPlace
Why Is Benefitfocus (BNFT) Stock Up 48% Today?
Via InvestorPlace
Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today?
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
Via Benzinga
What 4 Analyst Ratings Have To Say About Arcturus Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Rogers Shares Are Trading Sharply Lower; Here Are 33 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Match Group, Super Micro Computer And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.